Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
David A Bond, Lapo Alinari Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of patho...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-05-01
|
| Series: | Journal of Blood Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/emerging-treatment-options-for-the-management-of-hodgkins-lymphoma-cl-peer-reviewed-article-JBM |
| _version_ | 1818419152404086784 |
|---|---|
| author | Bond DA Alinari L |
| author_facet | Bond DA Alinari L |
| author_sort | Bond DA |
| collection | DOAJ |
| description | David A Bond, Lapo Alinari Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through copy number alterations, polysomy, and amplification of the 9p24.1 locus encoding PD-L1. By engaging with PD-1+ T-cells, PD-L1 delivers a potent immune suppressive signal promoting immunologic escape of the tumor cell. Enhancing antitumor immune response by targeting PD-1 with the monoclonal antibody nivolumab has proved to be effective in multiple solid tumors, but the highest response rates to date have been reported in patients with cHL, with over 65% of treated patients achieving an objective clinical response. In this review, we will summarize the published evidence regarding the activity of nivolumab in cHL as well as its current place in therapy. We will review the pharmacology, mechanism of action, and side effects of nivolumab as well as the emerging data indicating possible increased risk of graft versus host disease in patients treated with PD-1 inhibitors either pre- or post-allogeneic stem cell transplant. Given the remarkable single-agent activity and safety profile of PD-1 inhibitors in heavily pretreated patients with cHL, the possibility of employing nivolumab in combination with other active agents and earlier in therapy is a promising area of active investigation, and we will briefly summarize current clinical trials. Keywords: nivolumab, Hodgkin’s lymphoma, pembrolizumab, checkpoint inhibitor therapy |
| first_indexed | 2024-12-14T12:34:02Z |
| format | Article |
| id | doaj.art-775a214d048945a3a60ff7a0c86e0500 |
| institution | Directory Open Access Journal |
| issn | 1179-2736 |
| language | English |
| last_indexed | 2024-12-14T12:34:02Z |
| publishDate | 2017-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Blood Medicine |
| spelling | doaj.art-775a214d048945a3a60ff7a0c86e05002022-12-21T23:01:06ZengDove Medical PressJournal of Blood Medicine1179-27362017-05-01Volume 8415432797Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of NivolumabBond DAAlinari LDavid A Bond, Lapo Alinari Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through copy number alterations, polysomy, and amplification of the 9p24.1 locus encoding PD-L1. By engaging with PD-1+ T-cells, PD-L1 delivers a potent immune suppressive signal promoting immunologic escape of the tumor cell. Enhancing antitumor immune response by targeting PD-1 with the monoclonal antibody nivolumab has proved to be effective in multiple solid tumors, but the highest response rates to date have been reported in patients with cHL, with over 65% of treated patients achieving an objective clinical response. In this review, we will summarize the published evidence regarding the activity of nivolumab in cHL as well as its current place in therapy. We will review the pharmacology, mechanism of action, and side effects of nivolumab as well as the emerging data indicating possible increased risk of graft versus host disease in patients treated with PD-1 inhibitors either pre- or post-allogeneic stem cell transplant. Given the remarkable single-agent activity and safety profile of PD-1 inhibitors in heavily pretreated patients with cHL, the possibility of employing nivolumab in combination with other active agents and earlier in therapy is a promising area of active investigation, and we will briefly summarize current clinical trials. Keywords: nivolumab, Hodgkin’s lymphoma, pembrolizumab, checkpoint inhibitor therapyhttps://www.dovepress.com/emerging-treatment-options-for-the-management-of-hodgkins-lymphoma-cl-peer-reviewed-article-JBMnivolumab Hodgkins lymphoma pembrolizumab checkpoint inhibitor therapy |
| spellingShingle | Bond DA Alinari L Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab Journal of Blood Medicine nivolumab Hodgkins lymphoma pembrolizumab checkpoint inhibitor therapy |
| title | Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab |
| title_full | Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab |
| title_fullStr | Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab |
| title_full_unstemmed | Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab |
| title_short | Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab |
| title_sort | emerging treatment options for the management of hodgkin 39 s lymphoma clinical utility of nivolumab |
| topic | nivolumab Hodgkins lymphoma pembrolizumab checkpoint inhibitor therapy |
| url | https://www.dovepress.com/emerging-treatment-options-for-the-management-of-hodgkins-lymphoma-cl-peer-reviewed-article-JBM |
| work_keys_str_mv | AT bondda emergingtreatmentoptionsforthemanagementofhodgkin39slymphomaclinicalutilityofnivolumab AT alinaril emergingtreatmentoptionsforthemanagementofhodgkin39slymphomaclinicalutilityofnivolumab |